HK1208630A1 - Methods for treating neutropenia using retinoid agonists - Google Patents

Methods for treating neutropenia using retinoid agonists

Info

Publication number
HK1208630A1
HK1208630A1 HK15109432.0A HK15109432A HK1208630A1 HK 1208630 A1 HK1208630 A1 HK 1208630A1 HK 15109432 A HK15109432 A HK 15109432A HK 1208630 A1 HK1208630 A1 HK 1208630A1
Authority
HK
Hong Kong
Prior art keywords
methods
retinoid agonists
treating neutropenia
neutropenia
treating
Prior art date
Application number
HK15109432.0A
Other languages
English (en)
Chinese (zh)
Inventor
Lingtao Wu
Original Assignee
Los Angeles Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Los Angeles Childrens Hospital filed Critical Los Angeles Childrens Hospital
Publication of HK1208630A1 publication Critical patent/HK1208630A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
HK15109432.0A 2012-06-07 2015-09-24 Methods for treating neutropenia using retinoid agonists HK1208630A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261656815P 2012-06-07 2012-06-07
PCT/US2013/044828 WO2013185105A1 (fr) 2012-06-07 2013-06-07 Méthodes de traitement de la neutropénie à l'aide d'agonistes de rétinoïde

Publications (1)

Publication Number Publication Date
HK1208630A1 true HK1208630A1 (en) 2016-03-11

Family

ID=49712715

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15109432.0A HK1208630A1 (en) 2012-06-07 2015-09-24 Methods for treating neutropenia using retinoid agonists

Country Status (14)

Country Link
US (1) US11116738B2 (fr)
EP (1) EP2858636B1 (fr)
JP (1) JP6295249B2 (fr)
KR (1) KR102083046B1 (fr)
CN (1) CN104519879B (fr)
AU (1) AU2013270674B2 (fr)
BR (1) BR112014030279A2 (fr)
CA (1) CA2874850A1 (fr)
ES (1) ES2691493T3 (fr)
HK (1) HK1208630A1 (fr)
MX (1) MX365321B (fr)
NZ (1) NZ702415A (fr)
RU (1) RU2650962C2 (fr)
WO (1) WO2013185105A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10286039B2 (en) 2014-02-18 2019-05-14 Children's Hospital Los Angeles Compositions and methods for treating neutropenia
US11116738B2 (en) 2012-06-07 2021-09-14 Children's Hospital Los Angeles Methods for treating neutropenia using retinoid agonists

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2906800A1 (fr) 2013-03-15 2014-09-18 Avisenna Cosmetics, Llc Compositions topiques permettant de reduire les effets du vieillissement
AU2016243702B2 (en) * 2015-03-31 2021-10-07 Syros Pharmaceuticals, Inc. Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists
US9868994B2 (en) 2016-04-08 2018-01-16 Syros Pharmaceuticals, Inc. Methods of stratifying patients for treatment with retinoic acid receptor-α agonists
WO2018067946A1 (fr) * 2016-10-06 2018-04-12 Syros Pharmaceuticals, Inc. Méthodes de traitement de patients à l'aide d'un agoniste du récepteur alpha de l'acide rétinoïque et d'un anticorps anti-cd38
EP3743722A4 (fr) * 2018-01-26 2022-03-02 Agency for Science, Technology and Research Sous-types de neutrophiles
CN113969261B (zh) * 2020-07-06 2024-04-09 苏州市立医院(北区) 三步法快速测定中性粒细胞趋化的方法
US20220378727A1 (en) * 2021-05-14 2022-12-01 The University Of Hong Kong Dry powder formulations of tamibarotene for pulmonary and intranasal delivery

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691196A (en) 1992-12-31 1997-11-25 American Cyanamid Company Recombinant nucleic acid containing a response element
US5965606A (en) * 1995-12-29 1999-10-12 Allergan Sales, Inc. Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity
ZA9711342B (en) * 1996-12-19 1999-06-17 American Cyanamid Co Method of treating or inhibiting neutropenia
JP2004524005A (ja) 2000-09-08 2004-08-12 マサチューセッツ　インスティテュート　オブ　テクノロジー Ｇ−ｃｓｆアナログ組成物および方法
US7119061B2 (en) 2002-11-18 2006-10-10 Vicuron Pharmaceuticals, Inc. Dalbavancin compositions for treatment of bacterial infections
EP1632241A4 (fr) 2003-05-16 2009-07-22 Kyowa Hakko Kirin Co Ltd Preventif et/ou remede pour des maladies accompagnees de destruction tissulaire
EP1621191A1 (fr) * 2004-07-29 2006-02-01 Werner Bollag Traitement de maladies inflammatoires avec des antagonistes du RXR
AU2005272653A1 (en) * 2004-08-13 2006-02-23 Anormed Inc. Chemokine combinations to mobilize progenitor/stem cells
NZ555075A (en) 2004-12-02 2011-02-25 Venus Remedies Ltd Compositions for combating beta-lactamase-mediated antibiotic resistance using ceftriaxone, sulbactam and EDTA
US20090111786A1 (en) 2004-12-03 2009-04-30 Glass Christopher K Compounds that Prevent Macrophage Apoptosis and Uses Thereof
TR201819157T4 (tr) 2006-05-16 2019-01-21 Io Therapeutics Llc Kemoterapi Ve Veya Radyasyon Terapisinin Yan Etkilerinin Tedavisinde Kullanıma Yönelik Rar Antagonisti Veya Ters Agonisti
MX2009009997A (es) * 2007-03-30 2009-12-08 Tmrc Co Ltd Preparacion de la capsula de tamibarotene.
MX2010006213A (es) * 2007-12-06 2010-09-07 Csl Ltd Metodo de inhibicion de celulas madre leucemicas.
WO2010028388A1 (fr) 2008-09-05 2010-03-11 Solulink Biosciences, Inc. Procédés et compositions pour la détection directe de lésions de l’adn
WO2011048617A2 (fr) 2009-10-19 2011-04-28 Laila Nutraceuticals Extraits, fractions et compositions comprenant des acetogenines et leurs applications
RU2446173C1 (ru) 2010-08-13 2012-03-27 Зао "Биокад" Новый функционально активный, высокоочищенный стабильный конъюгат гранулоцитарного колониестимулирующего фактора (г-ксф) с полиэтиленгликолем с пролонгированным биологическим действием, пригодный для медицинского применения, и иммунобиологическое средство на его основе
CN102380090A (zh) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 G-csf二聚体在治疗嗜中性粒细胞减少症中的应用
WO2012109208A2 (fr) 2011-02-08 2012-08-16 Cellular Dynamics International, Inc. Production de précurseurs hématopoïétiques obtenus par programmation
WO2013169864A2 (fr) * 2012-05-08 2013-11-14 Lycera Corporation Tétrahydro[1,8]naphtyridine-sulfonamide et composés apparentés pour utilisation en tant qu'agonistes de rorγ et dans le traitement d'une maladie
ES2691493T3 (es) 2012-06-07 2018-11-27 Childrens Hospital Los Angeles Métodos para tratar la neutropenia usando agonistas retinoides
DE102012011766B3 (de) 2012-06-15 2013-12-19 Voith Patent Gmbh Getriebeeinheit
CN110946993A (zh) 2014-01-03 2020-04-03 上海泽生科技开发股份有限公司 纽兰格林制剂的配方
AU2015219038B2 (en) 2014-02-18 2018-10-18 Children's Hospital Los Angeles Compositions and methods for treating neutropenia

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11116738B2 (en) 2012-06-07 2021-09-14 Children's Hospital Los Angeles Methods for treating neutropenia using retinoid agonists
US10286039B2 (en) 2014-02-18 2019-05-14 Children's Hospital Los Angeles Compositions and methods for treating neutropenia

Also Published As

Publication number Publication date
EP2858636B1 (fr) 2018-09-05
AU2013270674B2 (en) 2017-12-07
RU2014153988A (ru) 2016-07-27
CN104519879B (zh) 2018-10-02
BR112014030279A2 (pt) 2017-09-12
KR102083046B1 (ko) 2020-02-28
US20150164836A1 (en) 2015-06-18
JP6295249B2 (ja) 2018-03-14
JP2015523346A (ja) 2015-08-13
MX365321B (es) 2019-05-29
CN104519879A (zh) 2015-04-15
WO2013185105A1 (fr) 2013-12-12
NZ702415A (en) 2016-04-29
ES2691493T3 (es) 2018-11-27
KR20150035983A (ko) 2015-04-07
AU2013270674A1 (en) 2014-12-18
CA2874850A1 (fr) 2013-12-12
EP2858636A4 (fr) 2016-06-01
MX2014014930A (es) 2015-07-06
EP2858636A1 (fr) 2015-04-15
RU2650962C2 (ru) 2018-04-18
US11116738B2 (en) 2021-09-14

Similar Documents

Publication Publication Date Title
HK1212879A1 (zh) 電外科設備
HK1214504A1 (zh) 用於治療貧血的方法
EP2766018A4 (fr) Composés agonistes de rxr et procédés associés
EP2787497A4 (fr) Appareil d'évaluation de défaut
HK1208630A1 (en) Methods for treating neutropenia using retinoid agonists
ZA201405746B (en) Rafamycin analogs and methods for making same
EP2871630A4 (fr) Appareil de prolongement de la veille
GB201218666D0 (en) Apparatus
PL2825704T3 (pl) Urządzenie do oczyszczania drogi
GB201220673D0 (en) Apparatus
GB201202147D0 (en) Interface apparatus
PL2809816T3 (pl) Sposób ekspresji
GB201300914D0 (en) Apparatus
EP2880048A4 (fr) Procédé
PL2917455T3 (pl) Aparat pobierający próbki
EP2813146A4 (fr) Appareil de pêche de poissons
GB201218575D0 (en) Nephroureterectomy apparatus
HK1209999A1 (en) Apparatus
GB201202198D0 (en) Method
GB201311406D0 (en) Club-swing practice apparatus
GB201215796D0 (en) Apparatus
HK1209040A1 (en) Methods for treating vestibulotoxicity
GB201116152D0 (en) Cannabinoid-2-receptor agonists
ZA201409241B (en) Fishing apparatus
TWI561687B (en) An electroplating method

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230609